Free Trial

IDEAYA Biosciences (NASDAQ:IDYA) Earns Neutral Rating from Analysts at The Goldman Sachs Group

IDEAYA Biosciences logo with Medical background

The Goldman Sachs Group started coverage on shares of IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) in a research note issued on Thursday. The brokerage set a "neutral" rating and a $25.00 price target on the stock. The Goldman Sachs Group's target price would indicate a potential upside of 11.68% from the company's previous close.

Other research analysts have also recently issued research reports about the stock. Royal Bank Of Canada upgraded shares of IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and lowered their target price for the company from $57.00 to $30.00 in a research note on Wednesday. Wells Fargo & Company began coverage on shares of IDEAYA Biosciences in a research note on Thursday, June 26th. They set an "overweight" rating and a $44.00 price target for the company. Finally, JPMorgan Chase & Co. boosted their price objective on shares of IDEAYA Biosciences from $63.00 to $66.00 and gave the company an "overweight" rating in a research report on Thursday, May 22nd. Three investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $47.55.

Read Our Latest Research Report on IDYA

IDEAYA Biosciences Price Performance

NASDAQ IDYA traded down $0.59 during trading on Thursday, hitting $22.39. 74,075 shares of the company's stock traded hands, compared to its average volume of 1,009,877. The stock has a fifty day moving average of $20.46 and a two-hundred day moving average of $20.55. IDEAYA Biosciences has a 12-month low of $13.45 and a 12-month high of $44.42. The firm has a market cap of $1.96 billion, a P/E ratio of -6.24 and a beta of 0.03.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same period in the prior year, the firm posted ($0.53) EPS. As a group, analysts expect that IDEAYA Biosciences will post -3.07 earnings per share for the current fiscal year.

Institutional Trading of IDEAYA Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. CWM LLC boosted its holdings in IDEAYA Biosciences by 325.7% during the first quarter. CWM LLC now owns 2,371 shares of the company's stock worth $39,000 after buying an additional 1,814 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in IDEAYA Biosciences by 180.2% during the first quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company's stock worth $39,000 after buying an additional 1,546 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in IDEAYA Biosciences during the fourth quarter worth $47,000. Signaturefd LLC boosted its holdings in IDEAYA Biosciences by 374.8% during the first quarter. Signaturefd LLC now owns 2,877 shares of the company's stock worth $47,000 after buying an additional 2,271 shares in the last quarter. Finally, Parallel Advisors LLC boosted its holdings in IDEAYA Biosciences by 72.4% during the second quarter. Parallel Advisors LLC now owns 3,260 shares of the company's stock worth $69,000 after buying an additional 1,369 shares in the last quarter. Institutional investors and hedge funds own 98.29% of the company's stock.

IDEAYA Biosciences Company Profile

(Get Free Report)

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.

Featured Articles

Analyst Recommendations for IDEAYA Biosciences (NASDAQ:IDYA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in IDEAYA Biosciences Right Now?

Before you consider IDEAYA Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEAYA Biosciences wasn't on the list.

While IDEAYA Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines